BioNTech Results Presentation Deck
Strong Performance in the First Half of 2021
Second Quarter
2021 Highlights
8
COVID-19 vaccine*
Shipped >1 billion doses to >100 countries & territories worldwide
Signed supply contracts for ~2.2 billion doses for delivery in 2021
Committed to deliver >2 billion doses to low- and middle-income nations.
Continued pipeline expansion
Randomized Phase 2 trial starts
Melanoma FixVac: BNT111 (CPI-R/R)
HPV16 Fix Vac: BNT113 (HPV16+ HNSCC)
iNeST: BNT122 (Adjuvant CRC)
Further corporate updates
Reported Q2 total revenues of €5.3 billion
• Jens Holstein appointed to Management Board as CFO as of July 1, 2021
●
Acquired personalized TCR platform and cGMP manufacturing facility from Kite Pharma
●
●
First-in-Human Phase 1 trial starts
CARVac: BNT211 (Multiple solid tumors)
NEOSTIM: BNT221 (Multiple s.t.)
RiboCytokines: BNT151/2/3 (Multiple s.t.)
"As of July 21, 2021: includes doses shipped by collaboration partner Pfizer;
s.t., solid tumors;
BIONTECHView entire presentation